Outcomes17

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 17 of 17

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Patients Who Experienced Adverse Events (AEs) in the MP	First MP dose up to 1 day (2 days for QOD regimen) after last MP dose.	The safety analysis set for the MP (SAF-MP) included all patients treated with at least 1 dose of MP ZS and who had any MP safety data.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Percentage of Patients Who Were Normokalemic in the MP	MP Day 1 to End of Study visit (up to 12 months).	The full analysis set for the MP (FAS-MP) included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	Percentage of patients	NUMBER
SECONDARY	Percentage of Patients With Average S-K Levels of ≤5.1 mmol/L and ≤5.5 mmol/L in the MP	MP Day 2 to Day 362.	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	Percentage of patients	NUMBER
SECONDARY	Percentage of Patients Who Were Hypokalemic in the MP	MP Day 1 to End of Study visit (up to 12 months).	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	Percentage of patients	NUMBER
SECONDARY	Percentage of Patients Who Were Hyperkalemic in the MP	MP Day 1 to End of Study visit (up to 12 months).	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	Percentage of patients	NUMBER
SECONDARY	Mean Change From CP Baseline in the Mean S-K Level Over Specified Time Periods in the MP	CP Day 1 to MP Day 362.	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	mmol/L	MEAN
SECONDARY	Mean Change From MP Baseline in the Mean S-K Level Over Specified Time Periods in the MP	MP Day 1 to Day 362.	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	mmol/L	MEAN
SECONDARY	Mean Number of Normokalemic Days During the MP	MP Day 1 to Day 362.	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	Days	MEAN
SECONDARY	Mean Change in S-K Level From Last On-treatment MP Visit to the End of Study	MP Day 1 to End of Study visit (up to 12 months).	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	mmol/L	MEAN
SECONDARY	Change From CP Baseline in S-Aldosterone Levels Over the MP	CP Day 1, MP Day 166 and MP Day 362.	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	Picomole per liter (pmol/L)	MEAN
SECONDARY	Percentage of Patients With Normal S-Aldosterone Levels Over the MP	CP Day 1, MP Day 166 and MP Day 362.	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	Percentage of patients	NUMBER
SECONDARY	Change From CP Baseline in S-Bicarbonate Levels Over the MP	CP Day 1, and MP Day 1 to End of Study visit (up to 12 months).	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	mmol/L	MEAN
SECONDARY	Percentage of Patients With Normal S-Bicarbonate Levels Over the MP	CP Day 1 and MP Day 1 to End of Study visit (up to 12 months).	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	Percentage of patients	NUMBER
SECONDARY	Baseline and Post-baseline 36-Item Short Form Health Survey Version 2 (SF-36 v2) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores	CP Day 1 (baseline) and MP Day 362 (post-baseline).	The FAS-MP included all patients who received at least 1 dose of ZS during the MP and who had any post-baseline MP S-K values.	Scale score	MEAN
SECONDARY	Mean Change From CP Baseline in the Mean S-K Levels in the CP	CP Day 1 to Day 3.	The CP full analysis set (FAS-CP) included all patients who received at least 1 dose of ZS during the CP and who had any post-baseline CP S-K values.	mmol/L	MEAN
SECONDARY	Percentage of Patients Who Were Normokalemic in the CP	CP Day 1 to Day 3.	The FAS-CP included all patients who received at least 1 dose of ZS during the CP and who had any post-baseline CP S-K values.	Percentage of patients	NUMBER
SECONDARY	Number of Patients Who Experienced AEs in the CP	Day 1 of CP to last CP dose + 1 day or first MP dose -1 day, earlier.	The SAF-CP included all patients treated with at least 1 dose of CP ZS and who had any CP safety data.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03172702/outcomes

API reference For AI assistants